Medable and Masimo partners to bring best-in-class mobile devices to clinical trials, capturing rich subjective and objective data

The partnership enables deeper evidence generation in clinical trials; early success in eight oncology trials sponsored by large pharmaceutical companies

PALO ALTO, California, May 29, 2024–(BUSINESS WIRE)–Medable Inc., a leading technology provider for modern clinical trials, partners with industry leader Masimo (NASDAQ: MASI) to bring best-in-class medical-grade portable devices to clinical trials. Masimo’s award-winning pulse oximeter technology has been trusted by clinicians for over 25 years to monitor over 200 million patients each year and now enables more patients to participate in clinical trials without the need for ongoing visits to a study site for routine testing.

Medable has integrated Masimo’s MightySat^® Pulse Oximeter Rx for Evidence Generation Platform in eight big-pharma-sponsored clinical trials conducted in 25 countries, enrolling more than 3,000 patients with two oncology indications: lung cancer and breast cancer. Device integration eliminates the significant travel burden of often very sick patients, while enabling them to participate in potentially life-saving clinical trials. Through this collaboration, Medable also enables both subjective data capture – through humans via Medable’s eCOA+ solution – and objective data capture via connected Masimo sensors for multi-faceted, deeper data analysis in research.

“Medable has always been a leader in digital and decentralized clinical research, and we are excited to partner with a forward-thinking organization that has the ambition and ability to transform research,” said Dr. Daniel Cantillon, chief medical officer at Masimo. “Clinical research requires best-in-class accuracy and data quality both on-site and outside clinical offices. Medable is solving this problem through its support and enabling more patients to participate in trials. Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”

Medable selected Masimo for its unrivaled reputation and unique signal extraction technology^® which provides accurate readings even under difficult conditions such as patient movement or low perfusion.

“Masimo SET^® Pulse oximetry is sensitive enough to capture key vital signs of the very sick, such as cancer patients, and it works on all skin tones, ages, and is easy to use,” said Musaddiq Khan, vice president of digital outcomes and strategy for TA at Medable. The Masimo team is great and we look forward to a long-term collaboration so that we can use more of their innovative wearable devices to improve data quality and enable patients to participate in research with less burden.”

The story continues

Currently, 20% of studies using Medable’s evidence generation platform involve wearables, and 35% of them are in oncology.

Medable, which was among the top 8% of software companies on Inc.’s 2023 list. 5000, has deployed its software-as-a-service platform in over 300 decentralized and hybrid clinical trials in 60 countries, serving over one million patients and trial participants worldwide. Customers achieved impressive results – including 200% faster registration and a 50% reduction in costs. A study by the Tufts Center for the Study of Drug Development shows that, on average, decentralized clinical trials can provide a net financial benefit of five to 13 times those of Phase II and III trials, equating to a return on investment of approximately $10 million and $39 million ROI for an average investment of PLN 500,000. dollars in phase II and $1.5 million in phase III.

To learn more about generating in-body evidence and how Medable uniquely supports oncology research, visit stand no. 35165 at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31-June 4) in Chicago, IL. You can also book a meeting here (info.medable.com/ASCO-meetings).

About Medable

Medable’s mission is to bring effective therapies to people faster. Its digital clinical trials platform increases the speed, scale and patient access to clinical trials, accelerating the dispensation of medicines for thousands of conditions without the need for treatment. Recognized as an industry leader by Everest Group and awarded best digital health solution by the Galien Foundation, the Medable platform has been implemented in over 300 studies in 60 countries and 120 languages, serving over one million patients worldwide. Medable is a privately held, venture-backed company based in Palo Alto, California, ranked 398 on Inc. 5,000 in 2023

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529956321/en/

Communication

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
[email protected] / [email protected]